VaccinesStudies updated this monthCOVID vaccines for children — what have we learned over the years?
What do Natural Therapy Specialists write?
By February 2021, VAERS reports indicated a link between myocarditis in young men and COVID vaccines.
From December 2020 to December 2022, more than 4,000 reports concerning COVID vaccines in VAERS involved myocarditis.
Prof. Sucharit Bhakdi describes studies that compared vaccinated and unvaccinated people and indicated that serious health problems occurred more often after vaccination.
Prof. Sucharit Bhakdi says that more than 650 million doses of mRNA COVID vaccines had been given in the U.S. by December 2022.
Jerzy Zięba cites a warning that people with allergies should not receive the Pfizer-BioNTech vaccine.
Dr. Norman Pieniążek claims that lipid nanoparticles containing mRNA can reach various cells and cause them to start producing the encoded substance.
Dr. Norman Pieniążek claims that problems with adverse reactions after COVID vaccination were known.
What does scientific research from PubMed · Europe PMC say?
We selected 5 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 124.
Aim of the study: As the epidemic progresses, universal vaccination against COVID-19 has been the trend, but there are still some doubts about the efficacy and safety of COVID-19 vaccines in adolescents, children, and even infants. To evaluate the safety, immunogenicity, and efficacy of COVID-19 vaccines in the population aged 0-17 years.
Results: There was a total of six randomized controlled trials included in this systematic review and meta-analysis, enrolling participants in the age range of 3-17 years, and containing three types of COVID-19 vaccines. Compared with mRNA vaccines and adenovirus vector vaccines, inactivated vaccines have a more satisfactory safety profile, both after initial (RR 1.40, 95% CI 1.04-1.90, P = 0.03) and booster (RR 1.84, 95% CI 1.20-2.81, P = 0.005) vaccination. The risk of adverse reactions was significantly increased after the first and second doses, but there was no significant difference between the first two doses (RR 1.00, 95%CI 0.99-1.02, P = 0.60). Nevertheless, the two-dose regimen is obviously superior to the single-dose schedule for immunogenicity and efficacy.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The mass vaccination of children against coronavirus 2019 disease (COVID-19) has been frequently debated. The risk-benefit assessment of COVID-19 vaccination versus infection in children has also been debated. This systematic review looked for answers to the question "was the vaccination of our children valuable and successful?"
Results: The search results revealed that the majority of the reported adverse events after COVID-19 vaccination in pediatrics were mild to moderate, with few being severe. Injection site discomfort, fever, headache, cough, lethargy, and muscular aches and pains were the most prevalent side effects. Few clinical studies recorded significant side effects, although the majority of these adverse events had nothing to do with vaccination. In terms of efficacy, COVID-19 disease protection was achieved in 90-95% of cases for mRNA vaccines, in 50-80% of cases for inactivated vaccines, and in 58-92% of cases for adenoviral-based vaccines in children and adolescents. Based on available data, COVID-19 immunizations appear to be safe for children and adolescents. Furthermore, multiple studies have proven that different types of vaccines can provide excellent protection against COVID-19 in pediatric populations.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Over 16 million children have been detected positive for the coronavirus disease 2019 (COVID-19) in the United States since the outbreak of the pandemic. In general, children infected with severe acute respiratory syndrome coronavirus type 2 tend to have lighter symptoms than adults.
Results: Although two doses of vaccine in children seem insufficient to prevent Omicron infection, the booster dose provides enhanced protection against infection and severe illness. Most importantly, the bivalent vaccine has been approved for use in the pediatric population to extend the immune response to currently circulating Omicron variant. And the immune protection afforded to newborns after maternal vaccination appears to last only 6 months. Therefore, in the current situation where the rate of virus mutation is accelerating and the COVID-19 pandemic is still severe, it is crucial to extend vaccine protection to children over 6 months of age to weave a tighter safety net.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: A large-scale vaccination of coronavirus disease-19 (COVID-19) in adults has been conducted for nearly a year, and there is a growing recognition that immunization for children is also essential. It has been months since emergency use of pediatric COVID-19 vaccine was approved, we reviewed the prevalence and transmission of COVID-19 in children.
Results: The prevalence of COVID-19 in children is reduced due to vaccination even in a Delta prevalent period, so an increase in the vaccination rate is needed in children. Although the precise role of children in the transmission requires more research to uncover, they likely played a significant role, according to the available literature. We also described four candidate COVID-19 vaccines for children on their safety and immunogenicity and the impact of severe acute respiratory syndrome coronavirus 2 variants on childhood vaccination. Safety issues on pediatric vaccines post-approval, like adverse events following immunization and adverse events of special interest require studies on long-term and effective regulatory mechanisms.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The COVID-19 vaccine saved millions of lives during the pandemic. Clinical trials at the time of authorization and approval showed remarkable effectiveness.
Results: Coverage restrictions may further reduce population vaccinations rates, resulting in higher virus community load and prolonged circulation. Although the US regulatory framework requires insurers to cover vaccines included on the Centers for Disease Control and Prevention (CDC) Immunization Schedules without cost sharing, the future placement of COVID-19 vaccines on these schedules is uncertain. Given the evidence and population benefits, we support ICER's recommendation for private payers to cover COVID-19 vaccines with no patient cost sharing. We further recommend no restrictions on coverage based on risk factors, regardless of CDC Immunization Schedules, which have recently been subject to considerable uncertainty.
“Not stated” does not mean nobody paid — the database does not always record it.
Sources (8)
- Prof. Sucharit Bhakdi — mRNA Vaccine Toxicity — M. Palmer i S. Bhakdi i in. (2023)
- Jerzy Zięba — Szczepionka Pfizer – efekty uboczne
- Dr Norman Pieniążek — Prof. Norman Pieniążek o szczepionkach mRNA i całej propagandzie wokół nich mówi jasno to, czego na Facebooku napisać NIE MOŻNA!
- Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis. · Front Public Health 2022
- COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful? · Vaccines (Basel) 2023
- Dilemmas and options for COVID-19 vaccination in children. · Ital J Pediatr 2023
- COVID-19 in children: epidemic issues and candidate vaccines. · Chin Med J (Engl) 2022
- Payers should cover COVID-19 vaccines for all ages and risk groups with no patient cost sharing. · J Manag Care Spec Pharm 2026
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.